{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:52:37Z","timestamp":1772196757835,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0148104","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T13:49:59Z","timestamp":1454680199000},"page":"e0148104","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort"],"prefix":"10.1371","volume":"11","author":[{"given":"Karin","family":"Neukam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Mira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Monje-Agudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"Ruiz-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"P\u00e9rez-Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"G\u00e1lvez-Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1310\/hct1504-151","article-title":"Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort","volume":"15","author":"A Di Biagio","year":"2014","journal-title":"HIV Clin Trials"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1310\/hct1303-171","article-title":"Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection","volume":"13","author":"B Ha","year":"2012","journal-title":"HIV Clin Trials"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3851\/IMP2738","article-title":"Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and\/or C","volume":"19","author":"CB Hurt","year":"2014","journal-title":"Antivir Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1468-1293.2012.00995.x","article-title":"No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients","volume":"13","author":"B Van Welzen","year":"2012","journal-title":"HIV Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/QAI.0000000000000585","article-title":"Risk of Liver Enzyme Elevation during Treatment with Ritonavir-boosted Protease Inhibitors among HIV-monoinfected and HIV\/HCV Coinfected Patients","volume":"69","author":"G Lapadula","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0b013e32835cb815","article-title":"Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients","volume":"27","author":"E Vispo","year":"2013","journal-title":"AIDS"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"JM Molina","year":"2014","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"JM Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"JL Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"C Orkin","year":"2013","journal-title":"HIV Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkn045","article-title":"Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis","volume":"61","author":"JA Pineda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1468-1293.2011.00933.x","article-title":"Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and\/or C virus coinfection","volume":"13","author":"J Rockstroh","year":"2012","journal-title":"HIV Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1310\/hct0706-319","article-title":"Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir\/ritonavir","volume":"6","author":"R Palacios","year":"2006","journal-title":"HIV Clin Trials"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jac\/dkr083","article-title":"Liver tolerance of raltegravir-containing antirretroviral therapy in HIV-infected patients with chronic hepatitis C","volume":"66","author":"J Macias","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1302-61","article-title":"Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV\/HCV-coinfected patients","volume":"13","author":"J Macias","year":"2012","journal-title":"HIV Clin Trials"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1310\/hct1302-83","article-title":"Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program","volume":"13","author":"A Lazzarin","year":"2012","journal-title":"HIV Clin Trials"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.biopha.2014.12.006","article-title":"Raltegravir-based therapy in a cohort of HIV\/HCV co-infected individuals","volume":"69","author":"L Taramasso","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"19574","DOI":"10.7448\/IAS.17.4.19574","article-title":"Efficacy and safety of etravirine-containing regimens in a large cohort of HIV\/HCV coinfected patients according to liver fibrosis","volume":"17","author":"JL Casado","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/jac\/dkr357","article-title":"Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV\/hepatitis C virus co-infected patients","volume":"66","author":"K Neukam","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref21","unstructured":"Grupo de Estudio del SIDA. GeSIDA\/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.gesida-seimc.org\/guias_clinicas.php?mn_MP=406&mn_MS=407\" xlink:type=\"simple\">http:\/\/www.gesida-seimc.org\/guias_clinicas.php?mn_MP=406&amp;mn_MS=407<\/ext-link>. Accessed 25 November 2015."},{"key":"ref22"},{"key":"ref23","unstructured":"European AIDS Clinical Society (EACS). Clinical Management and Treatment of Chronic HBV and HCV Co-infection in HIV-positive Persons. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html\" xlink:type=\"simple\">http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html<\/ext-link>. Accessed 25 November 2015."},{"key":"ref24","unstructured":"National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events 2004. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.niaid.nih.gov\/labsandresources\/resources\/daidsclinrsrch\/documents\/daidsaegradingtable.pdf\" xlink:type=\"simple\">http:\/\/www.niaid.nih.gov\/labsandresources\/resources\/daidsclinrsrch\/documents\/daidsaegradingtable.pdf<\/ext-link>. Accessed 25 November 2015."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/317449","article-title":"Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine","volume":"5","author":"EH Gisolf","year":"2000","journal-title":"Clin Infect Dis"},{"key":"ref26","first-page":"395","article-title":"Low incidence of severe hepatic toxicity with 1400\/100mg QD fosamprenavir\/ritonavir in HIV\/HCV-coinfected patients. The TEL-C study","volume":"25","author":"N Merchante","year":"2011","journal-title":"AIDS Patients Care STDS"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"1","author":"MS Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"L Mart\u00edn-Carbonero","year":"2003","journal-title":"HIV Clin Trials"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/apc.2006.0113","article-title":"Risk factors for grade 3\u20134 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy","volume":"21","author":"S Chihrin","year":"2007","journal-title":"AIDS Patient Care STDS"},{"key":"ref30","first-page":"856542","article-title":"Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV\/HCV Coinfected Patients","volume":"2010","author":"EL Heil","year":"2010","journal-title":"AIDS Res Treat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"L Aranzabal","journal-title":"Clin Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jac\/dkl214","article-title":"Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C","volume":"58","author":"JA Mira","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C","volume":"195","author":"P Barreiro","year":"2007","journal-title":"J Infect Dis"},{"key":"ref34","first-page":"1","article-title":"Plasma concentrations of efavirenz, darunavir\/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients","author":"L Calza","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FTD.0b013e31821c2772","article-title":"Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens","volume":"33","author":"M Regazzi","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref36","unstructured":"Vertex Pharmaceuticals. Incivek (Telaprevir) prescribing information. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf\" xlink:type=\"simple\">http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf<\/ext-link>. Accessed 25 November 2015."},{"key":"ref37","unstructured":"Merck Sharp &amp; Dohme. Victrelis (Boceprevir) prescribing information. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf\" xlink:type=\"simple\">https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/ext-link>. Accessed 25 November 2015."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/apc.2011.0092","article-title":"Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir\/ritonavir through 96 weeks in the CASTLE study","volume":"26","author":"C McDonald","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/apc.2013.0009","article-title":"Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up","volume":"27","author":"C Laprise","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"P Labarga","year":"2007","journal-title":"J Infect Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"JD Lundgren","year":"2015","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0148104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T05:18:51Z","timestamp":1567574331000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0148104"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0148104","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726123297.793514309","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}